Navigation Links
Ikaria Founding Scientist Named 2007 MacArthur Fellow
Date:9/26/2007

CLINTON, N.J., Sept. 26 /PRNewswire-USNewswire/ -- Mark Roth, Ph.D., an advisor and founding scientist of Ikaria, this week received a MacArthur Fellowship award, which includes a grant to further his research over the next five years.

Roth, a member of the Fred Hutchinson Cancer Research Center's Basic Sciences Division, received five years of "no-strings-attached" support from the John D. and Catherine T. MacArthur Foundation for his pioneering research in basic biology. Most notably, his research has pioneered reversible metabolic hibernation -- a finding that may have clinical benefits in humans.

"Mark is an extraordinarily talented scientist, as well as a great friend and colleague to the Ikaria team," said Ikaria Chairman and CEO David Shaw. "We are very pleased that the MacArthur Foundation recognized the importance of Mark's groundbreaking research through this prestigious award. We look forward to making the benefits of this research available to patients in the future."

In April 2005, Roth demonstrated the ability of the biological gas hydrogen sulfide to induce a state of reversible metabolic hibernation in mice, which may be a latent ability in all mammals. Temporary slowing of the metabolic rate, or inducing hibernation on demand, has the potential to lengthen the window of time that patients with trauma, stroke, cardiac arrest or surgery can be treated. In addition to increasing the time that transplant organs or tissues are viable outside the body, this expanded time window could help prevent injury and death from insufficient or inappropriate oxygen supply to organs and tissues.

Ikaria has submitted regulatory documents for hydrogen sulfide as an experimental drug. The company is expected to start a Phase I trial later this year.

The MacArthur Fellowship Program recognizes talented individuals who have shown exceptional originality and dedication in their creative pursuits. Its purpose is to invest in a person's "originality, insight, and potential," enabling recipients to exercise their own creative instincts for the benefit of human society. Since its start in 1981, the program has named 756 Fellows, including Roth, who was among the 24 recipients announced this week.

About Ikaria Holdings

Ikaria Holdings is a fully integrated biotherapeutics company focused on the development and commercialization of innovative in-hospital pharmaceutical products and drug/device combinations that improve the lives of patients. The company's INOmax(R) product (inhaled nitric oxide) is an FDA-approved drug for the treatment of pulmonary hypertension in newborns, and is extensively used in critical settings in the United States, Canada, Europe, Latin America and Asia. Ikaria has a staff of over 300 people and is headquartered in Clinton, N.J., with research facilities in Seattle and Madison, Wis., and manufacturing in Port Allen, La. For more information, please visit the company's Web site at http://www.ikaria.com.

To view a related press release from the Fred Hutchinson Cancer Research Center, visit http://www.fhcrc.org/about/ne/news/2007/09/25/roth.html

For more information on the MacArthur Fellowship Program, visit http://www.macfound.org/site/c.lkLXJ8MQKrH/b.855229/k.63D6/Macarthur_Founda tio n_Home.htm


'/>"/>
SOURCE Ikaria
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. UW computer scientists fighting computer virus "Cold War"
2. UW scientist, former WiCell director found stem cell company
3. Scientists find way to make human collagen in lab
4. Wisconsin scientists to be recognized for innovative biofuel technology
5. UW biophysical scientist honored as society fellow
6. UW scientist wins Pew grant to study little-known immune cells
7. UW-Madison scientists to mimic nature for newest cancer drugs
8. The Scientist magazine names Madison "hotspot" for biotechnology
9. UW scientists study strange material with communications potential
10. Scientists find nanotech method for examining cells
11. Scientist takes back patents and develops product others ignored
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):